> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Merck Dust Mite Allergy Therapy
- URL: https://www.fdaweb.com/fda-approves-merck-dust-mite-allergy-therapy/
- Published: 2017-03-02T12:00:00.000Z
- Updated: 2026-09-14T22:09:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138104

FDA has approved Merck, Sharp & Dohme’s Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite-induced nasal inflammation with or without eye inflammation in people aged 18 to 65 years. “Odactra exposes patients to house dust mite allergens, gradually training the immune system in order to reduce the frequency and severity of nasal and eye allergy symptoms,” an FDA [release](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544330.htm?ref=fdaweb.com) says. Approval was based on studies conducted in the U.S., Canada and Europe, involving about 2,500 people. “During treatment, participants taking Odactra experienced a 16% to 18% reduction in symptoms and the need for additional medications compared to those who received a placebo,” the agency says.